Last reviewed · How we verify
NCT03874637
FemPulse Therapy First-in-Human Experience
NA trial testing Treament in Urinary Bladder, Overactive in 15 participants. Completed in 17 May 2017.
17 May 2017
Quick facts
| Lead sponsor | FemPulse Corporation |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | crossover |
| Masking | triple |
| Primary purpose | other |
| Enrollment | 15 |
| Start date | 14 February 2017 |
| Primary completion | 17 May 2017 |
| Estimated completion | 17 May 2017 |
| Sites | 2 locations across United States |
Drugs / interventions tested
- Treament
- Sham Control — full drug profile →
Conditions studied
- Urinary Bladder, Overactive — all drugs for Urinary Bladder, Overactive →
Sponsor
FemPulse Corporation
Who can join
21 and older, female only, with Urinary Bladder, Overactive. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The purpose of this clinical trial is to investigate a new medical device treatment for Overactive Bladder (OAB) in women.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT03874637
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Urinary Bladder, Overactive
Currently open trials in the same condition.
- NCT06201013 — Vitamin D Treat-to-Target Strategy for Children With Overactive Bladder-Wet · NA · recruiting
- NCT07366918 — Comparison of the Efficacy of Perineal and Intravaginal Electrical Stimulation in Women With Idiopathic Overactive Bladd · NA · recruiting
- NCT06933407 — Elastographic Assessment of Suburethral Tissue in Continent and Incontinent Women · recruiting
- NCT05715268 — Wearables for the Bladder: an In-home Treatment Feasibility Pilot Study · NA · active not recruiting
- NCT06479720 — Efficacy of Solifenacin or Mirabegron With Local Estrogen Versus Combination Pharmacotherapy for Overactive Bladder · Phase 4 · recruiting
Other FemPulse Corporation trials
Trials by the same sponsor.
- NCT07195656 — Evaluation of a Non-Implanted Electrical Stimulation Device for Overactive Bladder (OAB) · NA · recruiting
- NCT06885099 — Ease of Use Study of the FemPulse System · NA · completed
- NCT06347380 — Usability Study of the FemPulse System · NA · completed
- NCT04001426 — Pilot Phase for an Acute Evaluation of a Non-Implantable Electrical Continence Device · NA · completed
- NCT03784170 — FemPulse Therapy for Overactive Bladder in Women · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03874637 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by FemPulse Corporation
- Last refreshed: 14 March 2019
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03874637.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing